Sugi Predict

Sugi Predict / Compounds / SCHEMBL2779293

SCHEMBL2779293

SCHEMBL2779293

O=C(O)[C@H](Cc1ccccc1)Nc1ccc2ccccc2c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 2/20 0.53
▸ PPARA Q07869 1/20 0.52
▸ KDM4E B2RXH2 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ GAA P10253 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ MME P08473 2/20 0.51
▸ ACE P12821 2/20 0.51
▸ CPA1 P15085 2/20 0.51
▸ ACE2 Q9BYF1 2/20 0.51
▸ TRHDE Q9UKU6 1/20 0.50
▸ FPR2 P25090 7/20 0.49
▸ MRGPRX4 Q96LA9 1/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ NPR3 P17342 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2779289 1.00 PPARG (0.53) PPARGPPARAKDM4ELMNAGAA
SCHEMBL15577702 0.88 FCER2 (0.53) PPARGPPARAKDM4ELMNAGAA
SCHEMBL30436738 0.86 ATM (0.51) PPARGPPARALMNAGAARAB9A
SCHEMBL31022161 0.85 MME (0.57) PPARGMMEACECPA1ACE2
SCHEMBL5342232 0.83 RAB9A (0.50) PPARGPPARAKDM4ELMNAGAA
SCHEMBL5377321 0.83 RAB9A (0.50) PPARGPPARAKDM4ELMNAGAA
SCHEMBL5342235 0.83 RAB9A (0.50) PPARGPPARAKDM4ELMNAGAA
SCHEMBL1533647 0.82 PPARG (0.58) PPARGMMEFPR2
SCHEMBL6250861 0.82 PPARG (0.58) PPARGMMEFPR2
SCHEMBL1533645 0.82 PPARG (0.58) PPARGMMEFPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973887-B1 AZA HETEROCYCLICS FOR THE TREATMENT OF MALARIA OR AIDS IMMUPHARMA FRANCE SA (FR) 2012-09-19 — — EP disclosed
US-20100291199-A1 Compositions and Methods For The Treatment and Prevention of Disease CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-11-18 — — US disclosed
EP-2248901-A1 Streptogramines and method for preparing same by mutasynthesis Aventis Pharma S.A. (FR) 2010-11-10 — — EP disclosed
EP-0770132-B1 NEW STREPTOGRAMINES AVENTIS PHARMA SA (FR) 2010-09-08 — — EP disclosed
US-7777030-B2 Compositions and methods for the treatment and prevention of disease Centre National de la Recherge Scientifique (CNRS) (FR) 2010-08-17 — — US disclosed
EP-1965806-B1 1, 3, 5-triazepin-2, 6-diones for the treatment of malaria IMMUPHARMA FRANCE SA (FR) 2010-08-11 — — EP disclosed
EP-1973887-A1 AZA HETEROCYCLICS FOR THE TREATMENT OF MALARIA OR AIDS Immupharma France SA (FR) 2008-10-01 — — EP disclosed
EP-1965806-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF DISEASE IMMUPHARMA FRANCE SA (FR) 2008-09-10 — — EP disclosed
US-20080033167-A1 Compositions and methods for synthesizing heterocyclic therapeutic compounds UREKA SARL (FR) 2008-02-07 — — US disclosed
US-20070293469-A1 Compositions and methods for the treatment and prevention of disease UREKA SARL (FR) 2007-12-20 — — US disclosed
WO-2007074170-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF DISEASE IMMUPHARMA FRANCE SA (FR) 2007-07-05 — — WO disclosed
WO-2007074171-A1 AZA HETEROCYCLICS FOR THE TREATMENT OF MALARIA OR AIDS IMMUPHARMA FRANCE SA (FR) 2007-07-05 — — WO disclosed
US-6833382-B2 By muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines; mutant strain employed is preferably derived from the strain S. pristinaespiralis SP92 AVENTIS PHARMA S.A. (FR) 2004-12-21 — — US disclosed
US-20020142947-A1 STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS AVENTIS PHARMA, S.A. 2002-10-03 — — US disclosed
US-6352839-B1 PREPARING VIRGINIAMYCINS FROM AN ENGINEERED MICROORGANISMS, HAVING THE ABILITY TO PREVENT BIOSYNTHESIS OF THE PRECURSOR ANTIBIOTIC; THE MICROORGANISM IS CULTURED IN THE PRESENCE OF A SECOND PRECURSOR AND THE STREPTOGRAMIN ANALOG IS RECOVERED AVENTIS PHARMA S.A. (FR) 2002-03-05 — — US disclosed
EP-0770132-A1 STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS Aventis Pharma S.A. (FR) 1997-05-02 — — EP disclosed
WO-1996001901-A1 STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS RHONE-POULENC RORER S.A. (FR) 1996-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100291199-A1 Compositions and Methods For The Treatment and Prevention of Disease DNPEP, VIP, PEPD PPARG 2886/4885PPARA 2448/4885KDM4E 3892/4885
US-20070293469-A1 Compositions and methods for the treatment and prevention of disease DNPEP, VIP, PEPD PPARG 2886/4885PPARA 2448/4885KDM4E 3892/4885
US-20080033167-A1 Compositions and methods for synthesizing heterocyclic therapeutic compounds DNPEP, VIP, NGLY1 PPARG 2952/4885PPARA 2682/4885KDM4E 3434/4885
US-20020142947-A1 STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS EMG1, FBL, SMS PPARG 4112/4885PPARA 3830/4885KDM4E 4243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.